Program Description / Statement of Need:

In 2007 it was reported that 7.8% of the US population has diabetes, a leading cause of death that is associated with: Heart disease and stroke, High blood pressure, Blindness, Kidney disease, Neuropathy, and Amputations. The cost of diabetes in 2007 was estimated at $174 billion. Of the different oral antidiabetic agents, the sulfonylureas, meglitinides, GLP-1 analogues, and DPPIV inhibitors all impact insulin secretion in the pancreas yet these agents work differently. As many of the agents are newer, it is important for the clinician to understand the differing mechanisms of action and responses for each agent.

Target Audience:

This activity has been designed to meet the educational needs of pharmacists, and other health care professionals working for state Medicaid programs who are interested in disease management programs for patients with diabetes, particularly in elderly patients, and those with serious mental illness.

Program Objectives:

After completing this activity, the participant should be better able to:

1. Recognize that greater reductions in morbidity and mortality among older diabetic patients may result from control of all cardiovascular risk factors rather than from tight glycemic control alone.

2. Describe that even with the Medicare Part D drug benefit, many older adults with diabetes will incur significant out-of-pocket expenses for their medications

3. Identify the causes of morbidity and mortality in people with serious mental illness

4. Recognize that cardiovascular disease is the leading cause of death in persons with mental illness and that type 2 diabetes is a contributor to this increased CV risk

Accreditation:

ACPE Accreditation Statement

Educational Review Systems, Inc is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Through attending this program, up to 1.5 contact hours (0.15 CEU’s) may be awarded and a statement of credit issued to you upon completion of a program evaluation form, posttest (with a pass rate of 70% or higher) and an attendance verification form. The statement of credit will be issued immediately following the successful completion of these forms.

Credit Designation - CE

The Educational Review Systems, Inc. designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education. (761-999-08-078-H01-P)

Sponsored by:

Live Symposium Date: September 30, 2007

Release Date: May 15, 2008

Expiration Date: May 14, 2010

Estimated time to complete activity: 1.5 hours

Cost of activity: No Charge. 

Media: Web based learning activity

Faculty:

Joe Biskupiak, PhD, MBA (moderator)
Universitsity of Utah

Jennifer Tijia, MD, MSCE
Assistant Professor of Medicine
University of Massachusetts Medical School

Ronald Aubert, PhD
Vice-President
Medco

Julie Kreyenbuhl, PhD
Assistant Professor
Department of Psychiatry
University of Maryland School of Medicine

Faculty Disclosures

Viewing Requirements:

On-line symposium: Diabetes Management in Patients with Government Supported Benefits

Instructions:

• Read the learning objectives and faculty disclosures above

• Optionally, download and print the workbook so that you can take notes during the presentations

• View the on-line program. You may view this is more that one session, and may pause or repeat any portion of the presentation if you need to.

• Take the post-test

• Complete the program evaluation and CE registration/attendance verification. A CE certificate will be emailed to you within30 days upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Download Tjia Presentation (.pdfs of Slides) - optional

Download Aubert Presentation (.pdfs of Slides) - optional

Download Kreyenbuhl Presentation (.pdfs of Slides) - optional

View the On-line Video / Powerpoint Presentations

Perform Post-Test, Evaluation, and CE- Request

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your statement of credit will be issued to you immediately upon completion of this on-line program.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The JestaRx Group, Educational Resource Systesms, and the University of Utah do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of The JestaRx Group, Educational Resource Systesms, or the University of Utah. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Commercial Support:

Supported through an educational grant from: